Synthesis and evaluation as antitubercular agents of 5-arylethenyl and 5-(hetero)aryl-3-isoxazolecarboxylate

Drug Development Research

Volumn 74, Issue 3, 2013, Pages 162-172

  Vergelli, Claudia ^a   Cilibrizzi, Agostino ^a   Crocetti, Letizia ^a   Graziano, Alessia ^a   Dal Piaz, Vittorio ^a   Wan, Baojie ^b   Wang, Yuehong ^b   Franzblau, Scott ^b   Giovannoni, Maria Paola ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

3 isoxazolecarboxylic acid alkyl esters; antituberculosis agents; Mycobacterium tuberculosis

Indexed keywords

4 (2,6 DIMETHOXYPYRIDIN 3 YL) 4 HYDROXY 2 OXOBUT 3 ENOIC ACID ETHYL ESTER; 4 (4 CHLOROBENZOYL) 5 (2 NAPHTHALEN 1 YL VINYL) ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 4 BENZOYL 5 (2 BIPHENYL 4 YL VINYL) ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 4 BENZOYL 5 (2 BIPHENYL 4 YL VINYL) ISOXAZOLE 3 CARBOXYLIC ACID ISOPROPYL ESTER; 4 BENZOYL 5 (2 NAPHTHALEN 1 YL VINYL) ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 4 BENZOYL 5 [2 (4 CHLOROPHENYL) VINYL] ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 4 BENZOYL 5 STYRYL ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 4 HYDROXY 4 (7 METHOXYBENZOFURAN 2 YL) 2 OXOBUT 3 ENOIC ACID ETHYL ESTER; 5 (2,6 DIMETHOXYPYRIDIN 3 YL) ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 5 (2,6 DIMETHOXYPYRIDIN 3 YL) ISOXAZOLE 3 CARBOXYLIC ACID ISOPROPYL ESTER; 5 (7 METHOXYBENZOFURAN 2 YL) ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 5 (7 METHOXYBENZOFURAN 2 YL) ISOXAZOLE 3 CARBOXYLIC ACID ISOPROPYL ESTER; 5 (9H FLUOREN 2 YL) ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 5 ANTHRACEN 9 YL ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 5 ARYLETHENYL; 5 ARYLETHENYLISOXAZOLE CARBOXYLATE DERIVATIVE; 5 BENZO[B]THIOPHEN 2 YL ISOXAZOLE 3 CARBOXYLIC ACID; 5 BENZO[B]THIOPHEN 2 YL ISOXAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 5 BENZO[B]THIOPHEN 2 YL ISOXAZOLE 3 CARBOXYLIC ACID ISOPROPYL ESTER; 5 BIPHENYL 4 YL ISOXAZOLE 3 CARBOXYLIC ACID ISOPROPYL ESTER; 5 THIOPHEN 2 YL ISOXAZOLE 3 CARBOXYLIC ACID ISOPROPYL ESTER; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 84876149463     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21057     Document Type: Article

References (29)

1. Andries K, Verhasselt P, Guiellemont J, Gohlman HW, Neefs JM, Winkler H, Van Gestel J, Timmermann P, Zhu M, Lee E, et al. 2005. A diarylquinolone drug active and the ATP synthase of Mycobacterium tubercolosis. Science 307: 223-227.
2. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H,. 2009. HIV-associated opportunistic infections, going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis 48: 609-611.
3. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG,. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Micobacterium tubercolosis. Antimicrob Agents Chemother 51: 1380-1385.
4. Dal Piaz V, Ciciani G, Giovannoni MP,. 1991. New 6-ciano-3-phenyl-1,2,3, 4-tetrahydro-1,2-diazepin- 5-ones: synthesis and in vitro antitumor activity evaluation. Il Farmaco 46: 435-447.
5. Deavegowda VN, Jung H, Han KC, Yang EG, Choo H, Pae AN, Nam G, Chai K,. 2010. Novel 6-N-arylcarboxamidopyrazolo[4,3-d]pyrimidin-7-one derivatives as potential anti-cancer agents. Bioorg Med Chem Lett 20: 1630-1633.
6. Dorman SE, Chaisson RE,. 2007. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 3: 295-298.
7. Eswarana S, Adhikarib AV, Palc NK, Chowdhury IH,. 2010. Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antymicobacterial agents. Bioorg Med Chem Lett 20: 1040-1044.
8. Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG,. 2005. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 49: 1447-1454.
9. Fatutta S, Balestra M,. 1958. Ethyl p-phenylbenzoylpyruvate and its cyclization products. Gazz Chim Ital 88: 899-909.
10. Franzblau SG, Witzig RS, Mclaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, et al. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 36: 362-366.
11. Janculev J, Podolesov B,. 1961. Oxidative degradation of ethylaroyl pyruvates with lead tetraacetate. Croat. Chem. Acta 1: 59-64.
12. Janin YL,. 2007. Antitubercolosis drugs: ten years of research. Bioorg Med Chem 15: 2479-2513.
13. Johar M, Manning T, Kunimoto DY, Kumar R,. 2005. Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides. Bioorg Med Chem 13: 6663-6671.
14. Johnson R, Streicher EM, Louw GE, Warren RM, Van Helden PD, Victor TD,. 2006. Drug resistence Mycobacterium tuberculosis. Curr Issues Mol Biol 8: 97-112.
15. Lilienkampf A, Pieroni M, Wan B, Wang Y, Franzblau SG, Kozokowski AP,. 2010. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tubercolosis. A potent and selective series for further drug development. J Med Chem 53: 678-688.
16. Maggi N, Pasqualucci CR, Ballotta R, Sensi P,. 1966. Rifampicin, a new orally active rifamycin. Farmaco Sci 21: 68-75.
17. Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamvini JK,. 2007. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-ones diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem Lett 15: 1212-1228.
18. Pieroni M, Lilienkampf A, Wan B, Wang Y, Franzblau SG, Kozikowski AP,. 2009. Synthesis, biological evaluation and structure-activity relationship for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes. J Med Chem 52: 6287-6296.
19. Renzi G, Dal Piaz V, Musante C,. 1968. Condensation of chlorinated hydroxamic acid with β-oxobenzoyl compounds. Gazz Chim Ital 98: 656-666.
20. Russell DG, Barry CE, Flynn JL,. 2010. Tubercolosis: what we don't know can, and does, hurt us. Science 328: 852-856.
21. Spigelman MK,. 2007. New tubercolosis therapeutics: a growing pipeline. J Infect Dis 196: S28-S34.
22. Stover C, Warrener P, Vandevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, et al. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tubercolosis. Nature 405: 962-966.
23. Tangalapally RP, Sun D, Rakesh P, Budha N, Lee RB, Lenaerts AJ, Meibohm B, Lee RE,. 2007. Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorg Med Chem Lett 17: 6638-6642.
24. Thormann M, Almstetter M, Treml A, Heiser U, Buncholz M, Niestroj AJ,. 2008. 3-Hydroxy-1,5-dihydropyrrol-2-one derivatives as inhibitors of glutamynil cyclase for the treatment of ulcer, cancer and other diseases. PCT Int. Appl. WO 2008055945.
25. Wayne LG, Sohaskey CD,. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55: 139-163.
26. World Health Organization. 2002. Strategic framework to decrease the burden of TB/HIV document WHO/CDS/TB2002, 296, WHO/HIV AIDS/2002, 2. Geneva, Switzerland: World Health Organization.
27. World Health Organization. The Five Elements of DOTS. 2009. Geneva: World Health Organization. http://www.who.int/tb/dots/whatisdots/en/index.html.
28. World Health Organization. 2010. Tubercolosis fact sheet No. 104.
29. World Health Organization. 2010/2011. Tuberculosis, tuberculosis global facts.